AstraZeneca, Bristol Myers in $400 Billion Merger Talks

AstraZeneca Plc is reportedly in discussions to acquire Bristol Myers Squibb Co. in a potential merger valued at approximately $400 billion, according to sources familiar with the matter. The talks, which have been ongoing for several months, could create one of the world's largest drugmakers, positioning AstraZeneca as the fourth-largest by market capitalization. AstraZeneca's market value is about $263 billion, while Bristol Myers Squibb is valued at around $133 billion.

Strategic Implications

The merger would significantly enhance AstraZeneca's presence in the U.S. market, where Bristol Myers Squibb has a strong foothold. This move comes as Bristol is facing impending patent expirations on key products, including the blood thinner Eliquis and the cancer drug Opdivo, which together account for nearly half of its sales. In its latest quarterly report, Bristol Myers Squibb announced record sales of $13 billion, driven by newer treatments such as Breyanzi and Opdualag.

Potential Challenges

Both companies have substantial oncology divisions, which may attract antitrust scrutiny from regulators. The structure of the merger remains undecided, but it is expected to involve a combination of cash and shares. AstraZeneca's previous acquisition of Alexion in 2021, valued at $39 billion, would be surpassed by this potential deal. Concerns have also emerged in the UK regarding major companies shifting focus to the U.S. market, particularly following AstraZeneca's recent elevation of its New York listing.

Related coverage: Bain Capital Acquires Vitabiotics in $1 Billion Deal.